Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share News
  5. UK BROKER RATINGS SUMMARY: Barclays Downgrades Glaxo To Underweight

Pin to quick picksGlaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: Barclays Downgrades Glaxo To Underweight

Thu, 16th Jan 2020 09:38

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

BARCLAYS CUTS GLAXOSMITHKLINE TO 'UNDERWEIGHT' (EQUAL WEIGHT) - PRICE TARGET 1650 PENCE

----------

CREDIT SUISSE RAISES GLAXOSMITHKLINE PRICE TARGET TO 1860 (1800) PENCE - 'NEUTRAL'

----------

BARCLAYS RAISES ASTRAZENECA PRICE TARGET TO 8500 (8300) PENCE - 'OVERWEIGHT'

----------

CREDIT SUISSE RAISES ASTRAZENECA PRICE TARGET TO 8500 (8200) PENCE - 'OUTPERFORM'

----------

JEFFERIES CUTS DIAGEO TO 'HOLD' (BUY) - PRICE TARGET 3600 PENCE

----------

JPMORGAN RAISES SEGRO PRICE TARGET TO 855 (775) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES INFORMA PRICE TARGET TO 873 (869) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES BRITISH LAND CO PRICE TARGET TO 630 (605) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS PEARSON PRICE TARGET TO 860 (950) PENCE - 'OVERWEIGHT'

----------

UBS RAISES WPP PRICE TARGET TO 1175 (1125) PENCE - 'BUY'

----------

GOLDMAN REINITIATES VODAFONE WITH 'BUY' - PRICE TARGET 190 PENCE

----------

CREDIT SUISSE CUTS GLENCORE PRICE TARGET TO 300 (310) PENCE - 'OUTPERFORM'

----------

JPMORGAN RAISES BAE SYSTEMS PRICE TARGET TO 715 (700) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES MEGGITT PRICE TARGET TO 730 (685) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

JPMORGAN CUTS UNITE GROUP TO 'UNDERWEIGHT' ('NEUTRAL') - TARGET 1200 PENCE

----------

JPMORGAN CUTS BIG YELLOW TO 'UNDERWEIGHT' (NEUTRAL) - TARGET 1150 (1050) PENCE

----------

JPMORGAN RAISES WORKSPACE GROUP TARGET TO 1220 (1160) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES ST. MODWEN PROPERTIES TARGET TO 530 (490) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES HAMMERSON PRICE TARGET TO 300 (290) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES GREAT PORTLAND PRICE TARGET TO 880 (845) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES GRAINGER PRICE TARGET TO 330 (310) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES DERWENT LONDON TARGET TO 3720 (3500) PENCE - 'UNDERWEIGHT'

----------

JPMORGAN RAISES ASSURA GROUP PRICE TARGET TO 81 (79) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES ELECTROCOMPONENTS TO 'OVERWEIGHT' (NEUTRAL) - TARGET 774 (651) PENCE

----------

BARCLAYS CUTS SPIRENT TO 'UNDERWEIGHT' ('EQUAL WEIGHT') - TARGET 190 (159) PENCE

----------

JPMORGAN RAISES ULTRA ELECTRONICS PRICE TARGET TO 2400 (2200) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES QINETIQ PRICE TARGET TO 360 (340) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES DIPLOMA PRICE TARGET TO 1760 (1730) PENCE - 'NEUTRAL'

----------

JPMORGAN INITIATES PPHE HOTELS WITH 'OVERWEIGHT' - TARGET 2500 PENCE

----------

UBS RAISES ASHMORE GROUP PRICE TARGET TO 527 (480) PENCE - 'NEUTRAL'

----------

CREDIT SUISSE RAISES ASHMORE GROUP PT TO 480 (440) PENCE - 'UNDERPERFORM'

----------

OTHER MAIN MARKET AND AIM

----------

JPMORGAN CUTS INTU PROPERTIES PRICE TARGET TO 25 (29) PENCE - 'UNDERWEIGHT'

----------

JPMORGAN RAISES HELICAL PRICE TARGET TO 475 (450) PENCE - 'NEUTRAL'

----------

BARCLAYS RAISES GAMMA COMMUNICATIONS PRICE TARGET TO 1350 (1250) PENCE - 'OVERWEIGHT'

----------

BARCLAYS CUTS IQE TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 55 (73) PENCE

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
5678910111213

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.